Skip to content

Basket

You currently have no items in your basket.

AtaGenix

AtaGenix Laboratories, located in Wuhan, China, was established in 2012. The company evolved from ProteoGenix; a leading therapeutic antibody development service provider based in France. With a staff comprised of highly trained professionals from both countries, AtaGenix offers a wide range of catalogue products and custom services to meet a diversity of research requirements. 2BScientific customers regularly turn to us for AtaGenix’ antibody and protein reagents. We notice a lot of interest in the company’s primary antibodies against various small molecules, as well as in AtaGenix’ selection of human recombinant interleukin proteins, cytokines, and growth factors.

View All AtaGenix Products
AtaGenix
  • 100% guaranteed

More information on AtaGenix!

AtaGenix’ enzymes, ELISA kits, and molecular biology products are also very popular, and we regularly receive enquiries about AtaGenix’ vast portfolio of cDNA clones and gene expression vectors.

To support assay development and downstream research, AtaGenix integrates the company’s reagents and technical expertise to provide a variety of professional detection services. These include performance of mainstream techniques such as Western blotting, immunofluorescence, IHC, and ELISA, in addition to services to generate immunoprecipitation, ChIP, and real-time PCR data. Priding itself in using high quality reagents to deliver high quality data, AtaGenix makes many of the reagents used in-house available to customers for their own assays and screening programs.


As the main part of the modern biomedical industry, antibody drugs account for about 50% of global biopharmaceutical market. Antibody biosimilars are emerging biopharmaceutic market. Since the best-selling patents for several antibody drugs have expired, this provide an opportunity for antibody-drug analogues.

Antibody-drug analogues and biological original drugs contain similar active substances, which are similar in quality, safety and effectiveness, there is no difference in clinical significance. On November 7, 2019, the first adalimumab biosimilar drug BAT1406 was approved for marketing in China, which accelerated the development of antibody drugs. AtaGenix is now launching antibody-drug analogues to support the development of antibody drugs.

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.